Physician profile
Brian J Williams
NPI 1235162199
$875,932.93
in general payments reported to CMS, 2019-2025
26 companies · $308K in 2025
The $308K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $31K · 2021: $33K · 2022: $77K · 2023: $162K · 2024: $178K · 2025: $308K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $538K · Travel and Lodging: $46K · Honoraria: $31K · Consulting Fee: $21K · Food and Beverage: $12K · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $538,012.75 |
| Travel and Lodging | $45,633.07 |
| Honoraria | $30,860.08 |
| Consulting Fee | $21,289.64 |
| Food and Beverage | $12,119.46 |
| Education | $149.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $250,954.13 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Lilly USA, LLC | $224,909.63 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Dermavant Sciences, INC. | $89,657.30 | 2023-2024 | Vtama |
| Ucb, INC. | $78,532.35 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $57,630.34 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $54,237.74 | 2019-2025 | |
| Incyte Corporation | $45,557.37 | 2022-2025 | Opzelura, Opzelura |
| Organon LLC | $32,614.41 | 2025 | Vtama, Hadlima |
| Novartis Pharmaceuticals Corporation | $28,689.39 | 2019-2025 | Cosentyx |
| Dermira, INC. | $10,116.20 | 2019-2021 | |
| Abbvie INC. | $1,136.45 | 2019-2025 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $340.94 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $310.40 | 2019-2023 | |
| Janssen Biotech, INC. | $288.05 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $278.41 | 2019-2023 | Jublia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $175.86 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $77.49 | 2020 | |
| Amgen INC. | $76.55 | 2022-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $60.64 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $57.97 | 2023-2024 | Zoryve |
| Almirall LLC | $55.71 | 2025 | Seysara |
| Prugen, INC. Pharmaceuticals | $55.18 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $44.08 | 2020 | |
| Botanix Sb INC | $35.18 | 2025 | Sofdra |
| Mylan Pharmaceuticals INC. | $28.17 | 2019 | |
| Epi Health, LLC | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.